RxDoctor Payments Data

Ashma Shrestha, APRN

Nurse Practitioner · Farmington, CTNPI 1679346936

Payments from drug & device makers

What this record shows

This record is dominated by other: $12,083 of the $12,760 with a category attached, or 94.7%. Angiodynamics, Inc. accounts for 95.5% of it on its own, with 9 other manufacturers making up the rest. Among nurse practitioner clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,760in general payments, 2019–2025

Across 21 payments — averaging $607.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$12K
  • Endologix LLC$266
  • Johnson & Johnson$98
  • Tactile Systems Technology Inc$37
  • Smith+Nephew$36
  • Lemaitre Vascular, Inc.$36
  • plus $98 from 4 others

What the payments were for

  • Food & beverage$6765%
  • Other$12,08395%

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,760 in reported general payments places this provider in the 95th percentile of 1,162 nurse practitioner providers in Connecticut.

See all nurse practitioner providers in Connecticut

Medicare billing

Part B allowed, 2024
$32,504
Medicare patients
177
Services billed
288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban25$17,567
EliquisApixaban14$8,025
Cephalexin15$443
Gabapentin16$104
ClopidogrelClopidogrel Bisulfate11$73
Oxycodone Hcl11$54

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$98$17,56725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,162 nurse practitioner providers in Connecticut.

Other nurse practitioner in Farmington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →